Factors associated with switching from oral hypoglycaemic agents to insulin therapy

Netherlands Journal of Medicine

Volumn 60, Issue 6, 2002, Pages 243-248

  Spoelstra, J A ^a,b   Stolk, R P ^a   de Bruyne, M C ^a,c   Erkens, J A ^a,b   Herings, R M C ^b   Leufkens, H G M ^b   Grobbee, D E ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c Almere Primary Health Care Found   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA GLUCOSIDASE INHIBITOR; ANALGESIC AGENT; ANTIASTHMATIC AGENT; ANTIBIOTIC AGENT; ANTICOAGULANT AGENT; ANTIDEPRESSANT AGENT; ANTIFUNGAL AGENT; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BIGUANIDE; CALCIUM CHANNEL BLOCKING AGENT; CARDIAC AGENT; CARDIOVASCULAR AGENT; DOXAZOSIN; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCOSE; HEMOGLOBIN A1C; HYDRALAZINE; INSULIN; KETANSERIN; METFORMIN; NONSTEROID ANTIINFLAMMATORY AGENT; ORAL ANTIDIABETIC AGENT; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE; UNINDEXED DRUG; ANTIDIABETIC AGENT;

ACUTE HEART INFARCTION; ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL OBSERVATION; COMORBIDITY; CONTROLLED STUDY; DEPRESSION; FACTORIAL ANALYSIS; FEMALE; GENERAL PRACTITIONER; GLUCOSE BLOOD LEVEL; HEALTH CENTER; HEART ATRIUM FIBRILLATION; HUMAN; INSULIN TREATMENT; LABORATORY TEST; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; METABOLIC DISORDER; MICROALBUMINURIA; NETHERLANDS; NEUROPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; ONSET AGE; PROSTATE HYPERTROPHY; RETINOPATHY; METABOLISM; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; AGE OF ONSET; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; COMORBIDITY; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LONGITUDINAL STUDIES; MALE; MIDDLE AGED;

EID: 0036655133     PISSN: 03002977     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Polonsky KS, Sturis J, Bell GI. Non-insulin dependent diabetes mellitus - a genetically programmed failure of the beta cell to compensate for insulin resistance. N Engl J Med 1996;334:777-83.
2. Johnson JL, Wolf SL, Kabadi UM. Efficacy of insulin and sulphonylurea combination therapy in type II diabetes. Arch Intern Med 1996;156:259-64.
3. Koivisto VA. Insulin therapy in type II diabetes. Diabetes Care 1993;16(suppl 3):S29-S39.
4. Hayward RA, Manning WG, Kaplan SH, Wagner EH, Greenfield S. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. JAMA 1997;278:1663-9.
5. DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med 1999;131:281-303.
6. Skyler JS. Insulin therapy in type II diabetes. Who needs it, how much of it, and for how long? Postgrad Med 1997;101(2):85-96.
7. United Kingdom Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-53.
8. Miedema K, Veltmaat LJ, Reenders K. Switching to insulin therapy in NIDDM patients. A study of inhibiting factors in family practice. Huisarts Wet 1995;38:614-7.
9. Cromme PVM, Mulder JD, Rutten GEHM, Zuidweg J, Thomas S. NHG-Standard Diabetes Mellitus type II. Huisarts Wet 1989;32:15-8.
10. Rutten GEHM, Verhoeven S, Heine RJ, et al. NHG-standard Diabetes Mellitus type 2 (first revision). Huisarts Wet 1999;42:67-84.
11. Groop LC, Pelkonen R, Koskimies S, Bottazzo GF, Doniach D. Secondary failure to treatment with oral antidiabetic agents in non-insulin-dependent diabetes mellitus. Diabetes Care 1986;9:129-33.
12. Groop LC, Schalin C, Fransilla-Kallunki A, Widén E, Ekstrand A, Eriksson J. Characteristics of non-insulin-dependent diabetic patients with secondary failure to oral antidiabetic therapy. Am J Med 1989;87:83-90.
13. Goddijn PP. Improving metabolic control in NIDDM patients referred for insulin therapy (dissertation]. The Netherlands, University of Groningen: 1997.
14. Hunt LM, Valenzuela MA, Pugh JA. NIDDM patients' fears and hopes about insulin therapy. The basis of patient reluctance. Diabetes Care 1997;20:292-8.
15. Anonymous. Guidelines for Anatomical Therapeutic Chemical (ATC) classification. Oslo: WHO Collaboration centre for drug statistics methodology. Nordic Council on medicines, 1990.
16. Glauber HS, Brown JB. Use of health maintenance organisation databases to study pharmacy resource usage in diabetes mellitus. Diabetes Care 1992;15:870-6.
17. Metsemakers JFM, Höppener P, Knottnerus JA, Kocken RJJ, Limonard CBG. Computerized health information in the Netherlands: a registration network of family practices. Br J Gen Pract 1992;42:102-6.
18. Morris AD, Boyle DIR, MacAlpine R, et al. The diabetes audit and research in Tayside Scotland (DARTS) study: electronic database linkage to create a diabetes register. BMJ 1997;315:524-8.
19. Mooy JM, Grootenhuis PA, Vries H de, Valkenburg HA, Bouter LM, Heine RJ. Prevalence and determinants of glucose intolerance in a Dutch Caucasian population. The Hoorn Study. Diabetes Care 1995;18:1270-3.
20. Stolk RP, Pols HAP, Lamberts SWJ, Jong PT de, Hofman A, Grobbee DE. Diabetes mellitus, impaired glucose tolerance, and hyperinsulinemia in an elderly population. The Rotterdam Study. Am J Epidemiol 1997;145:24-32.
21. Burke JP, Williams K, Gaskill SP, et al. Rapid rise in the incidence of type 2 diabetes from 1987 to 1996. Results from the San Antonio Heart Study. Arch Intern Med 1999;159:1450-6.
22. Sonnaville JJJ de, Bouma M, Colly LP, Devillé W, Wijkel D, Heine RJ. Sustained good glycaemic control in NIDDM patients by implementation of structured care in general practice: 2-year follow-up study. Diabetologia 1997;40:1334-40.
23. United Kingdom Prospective Diabetes Study (UKPDS) Croup. UKPDS 17: a 9-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insulin-dependent diabetes mellitus. Ann Intern Med 1996;124:135-45.
24. Donnan PT, Steinke DT, Morris AD. The rate of failure of oral hypoglycaemic therapy in type 2 diabetes - a population-based study. Pharmacoepidem Dr S 2000;9(suppl 1):S91-S92.
25. Birkeland, KI, Hanssen KF, Urdal P, Berg K, Vaaler S. A long-term, randomized, comparative study of insulin versus sulphonylurea therapy in type 2 diabetes. J Intern Med 1994;236:305-13.
26. Ohkubo Y, Kishiwaka H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-17.
27. United Kingdom Prospective Diabetes Study (UKPDS) Group. UKPDS 26: Sulphonylurea failure in non-insulin-dependent diabetic patients over six years. Diabet Med 1998;15:297-303.
28. Konen JC, Curtis LG, Summerson JH. Symptoms and complications of adult diabetic patients in family practice. Arch Fam Med 1996;5:135-45.
29. Bouma M, Dekker JH, Eijk JThM van, Schellevis FG, Kriegsman DMW, Heine RJ. Metabolic control and morbidity of type 2 diabetic patients in a general practice network. Fam Pract 1999;16:402-6.
30. Ciechanowski PS, Katon WJ, Russo JE. Depression and diabetes: Impact of depressive symptoms on adherence, function, and costs. Arch Intern Med 2000;160:3278-85.